Advanced

A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer

Eberhard, Jakob LU ; Gaber, Alexander LU ; Wangefjord, Sakarias LU ; Nodin, Björn LU ; Uhlén, M; Ericson Lindquist, Kajsa LU and Jirström, Karin LU (2012) In British Journal of Cancer 106(5). p.931-938
Abstract

BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort.

METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malmö Diet and Cancer Study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancer-specific survival (CSS) and overall survival (OS).

RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41-0.92) and in colon... (More)

BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort.

METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malmö Diet and Cancer Study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancer-specific survival (CSS) and overall survival (OS).

RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41-0.92) and in colon cancer (HR=0.39; 95% CI 0.20-0.75), remaining significant in multivariable analysis of colon cancer (HR=0.49; 95% CI 0.25-0.96), with similar findings for OS. In curatively resected stage III-IV patients, a significant benefit from adjuvant and/or neoadjuvant therapy was observed for SATB2 high tumours (P(interaction)=0.037 for OS) and high SATB2 expression in rectal cancer correlated with an enhanced effect of neoadjuvant therapy (P(interaction)=0.033 for OS).

CONCLUSION: High SATB2 expression is an independent marker of good prognosis in colon cancer and may modulate sensitivity to chemotherapy and radiation.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Aged, Aged, 80 and over, Biomarkers, Tumor, Cohort Studies, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Humans, Kaplan-Meier Estimate, Matrix Attachment Region Binding Proteins, Neoplasm Staging, Prognosis, Proportional Hazards Models, Transcription Factors, Treatment Outcome, Journal Article, Research Support, Non-U.S. Gov't
in
British Journal of Cancer
volume
106
issue
5
pages
8 pages
publisher
Nature Publishing Group
external identifiers
  • wos:000300894300019
  • pmid:22333599
  • scopus:84857787822
ISSN
1532-1827
DOI
10.1038/bjc.2012.34
language
English
LU publication?
yes
id
e5eae6a7-5dc0-4914-bfef-2611d731fc19 (old id 2366917)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22333599?dopt=Abstract
date added to LUP
2012-03-02 11:37:58
date last changed
2017-10-22 04:53:03
@article{e5eae6a7-5dc0-4914-bfef-2611d731fc19,
  abstract     = {<p>BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort.</p><p>METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malmö Diet and Cancer Study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancer-specific survival (CSS) and overall survival (OS).</p><p>RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41-0.92) and in colon cancer (HR=0.39; 95% CI 0.20-0.75), remaining significant in multivariable analysis of colon cancer (HR=0.49; 95% CI 0.25-0.96), with similar findings for OS. In curatively resected stage III-IV patients, a significant benefit from adjuvant and/or neoadjuvant therapy was observed for SATB2 high tumours (P(interaction)=0.037 for OS) and high SATB2 expression in rectal cancer correlated with an enhanced effect of neoadjuvant therapy (P(interaction)=0.033 for OS).</p><p>CONCLUSION: High SATB2 expression is an independent marker of good prognosis in colon cancer and may modulate sensitivity to chemotherapy and radiation.</p>},
  author       = {Eberhard, Jakob and Gaber, Alexander and Wangefjord, Sakarias and Nodin, Björn and Uhlén, M and Ericson Lindquist, Kajsa and Jirström, Karin},
  issn         = {1532-1827},
  keyword      = {Aged,Aged, 80 and over,Biomarkers, Tumor,Cohort Studies,Colorectal Neoplasms,Gene Expression Regulation, Neoplastic,Humans,Kaplan-Meier Estimate,Matrix Attachment Region Binding Proteins,Neoplasm Staging,Prognosis,Proportional Hazards Models,Transcription Factors,Treatment Outcome,Journal Article,Research Support, Non-U.S. Gov't},
  language     = {eng},
  month        = {02},
  number       = {5},
  pages        = {931--938},
  publisher    = {Nature Publishing Group},
  series       = {British Journal of Cancer},
  title        = {A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer},
  url          = {http://dx.doi.org/10.1038/bjc.2012.34},
  volume       = {106},
  year         = {2012},
}